{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T03:56:56Z","timestamp":1781150216991,"version":"3.54.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007210","name":"Varian Medical Systems","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007210","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"DOI":"10.1186\/s13014-026-02848-3","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T12:44:26Z","timestamp":1778676266000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adjuvant stereotactic pancreatic radiotherapy (SPARTA trial): interim safety analysis of an ongoing phase II single center prospective study"],"prefix":"10.1186","volume":"21","author":[{"given":"Maria","family":"Massaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Comito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Franzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Teriaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Loi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Badalamenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariya B.","family":"Ilieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Lo Faro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Vernier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Tomatis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasqualina","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Bozzarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Rimassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Bonifacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Carrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Luigi","family":"Capretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Zerbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Scorsetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"issue":"11","key":"2848_CR1","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913\u201321. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-0155.","journal-title":"Cancer Res"},{"key":"2848_CR2","doi-asserted-by":"publisher","unstructured":"Gurusamy KS, Kumar S, Davidson BR, et al. Resection versus other treatments for locally advanced pancreatic cancer. Cochrane Database Syst Rev. 2014;2CD010244. https:\/\/doi.org\/10.1002\/14651858.CD010244.pub2.","DOI":"10.1002\/14651858.CD010244.pub2"},{"issue":"1","key":"2848_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RCA Siegel","year":"2021","unstructured":"Siegel RCA, Cancer. J Clin. 2021;71(1):7\u201333. https:\/\/doi.org\/10.3322\/caac.21654. Epub 2021 Jan 12.","journal-title":"J Clin"},{"key":"2848_CR4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s002689900215","volume":"21","author":"C Sperti","year":"1997","unstructured":"Sperti C, Pasquali C, Piccoli A, et al. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg. 1997;21:195\u2013200. https:\/\/doi.org\/10.1007\/s002689900215.","journal-title":"World J Surg"},{"key":"2848_CR5","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1007\/s11605-008-0762-x","volume":"13","author":"B Asiyanbola","year":"2009","unstructured":"Asiyanbola B, Gleisner A, Herman JM, et al. Determining Pattern of Recurrence Following Pancreaticoduodenectomy and Adjuvant 5-FlurouracilBased Chemoradiation Therapy: Effect of Number of Metastatic Lymph Nodes and Lymph Node Ratio. J Gastrointest Surg. 2009;13:752\u20139. https:\/\/doi.org\/10.1007\/s11605-008-0762-x.","journal-title":"J Gastrointest Surg"},{"key":"2848_CR6","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1200\/JCO.2008.17.7188","volume":"27","author":"CA Iacobuzio-Donahue","year":"2009","unstructured":"Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009;27:1806\u201313. https:\/\/doi.org\/10.1200\/JCO.2008.17.7188.","journal-title":"J Clin Oncol"},{"issue":"9","key":"2848_CR7","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s11605-009-0969-5","volume":"13","author":"DD You","year":"2009","unstructured":"You DD, Lee HG, Heo JS, et al. Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. J Gastrointest Surg. 2009;13(9):1699\u2013706. https:\/\/doi.org\/10.1007\/s11605-009-0969-5.","journal-title":"J Gastrointest Surg"},{"key":"2848_CR8","doi-asserted-by":"publisher","unstructured":"Conroy T, Hammel P, Hebbar M, et al. Canadian Cancer Trials Group and the Unicancer-GI\u2013PRODIGE Group. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018 Dec;20(25):2395\u2013406. https:\/\/doi.org\/10.1056\/NEJMoa1809775.","DOI":"10.1056\/NEJMoa1809775"},{"key":"2848_CR9","doi-asserted-by":"publisher","first-page":"3511","DOI":"10.1200\/JCO.2007.15.8782","volume":"26","author":"MM Corsini","year":"2008","unstructured":"Corsini MM, Miller RC, Haddock MG, et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975\u20132005). J Clin Oncol. 2008;26:3511\u20136. https:\/\/doi.org\/10.1200\/JCO.2007.15.8782.","journal-title":"J Clin Oncol"},{"key":"2848_CR10","doi-asserted-by":"publisher","unstructured":"Herman JM, Swartz MJ, Hsu CC, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol. 2008;26:3503\u201310. https:\/\/doi.org\/10.1200\/JCO.2007.15.8469.","DOI":"10.1200\/JCO.2007.15.8469"},{"issue":"4","key":"2848_CR11","doi-asserted-by":"publisher","first-page":"911e917","DOI":"10.1016\/j.ijrobp.2014.07.024","volume":"90","author":"AG Morganti","year":"2014","unstructured":"Morganti AG, Falconi M, Ruud GPM, van Stiphout, et al. Multi-institutional Pooled Analysis on Adjuvant Chemoradiation in Pancreatic Cancer. Int J Radiation Oncol Biol Phys. 2014;90(4):911e917. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.07.024","journal-title":"Int J Radiation Oncol Biol Phys"},{"issue":"6","key":"2848_CR12","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1097\/00000658-199912000-00006","volume":"230","author":"JH Klinkenbijl","year":"1999","unstructured":"Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230(6):776\u201382. https:\/\/doi.org\/10.1097\/00000658-199912000-00006. discussion 782-4.","journal-title":"Ann Surg"},{"key":"2848_CR13","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/s0140-6736(01)06651-x","volume":"358","author":"JP Neoptolemos","year":"2001","unstructured":"Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358:1576\u201385. https:\/\/doi.org\/10.1016\/s0140-6736(01)06651-x.","journal-title":"Lancet"},{"key":"2848_CR14","doi-asserted-by":"publisher","unstructured":"Neoptolemos JP, Stocken DD, Friess H, et al. European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004 Mar;18(12):1200\u201310. https:\/\/doi.org\/10.1056\/NEJMoa032295.","DOI":"10.1056\/NEJMoa032295"},{"issue":"8","key":"2848_CR15","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1038\/sj.bjc.6602513","volume":"92","author":"DD Stocken","year":"2005","unstructured":"Stocken DD, B\u00fcchler MW, Dervenis C, et al. Pancreatic Cancer Meta-analysis Group. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer. 2005;92(8):1372\u201381. https:\/\/doi.org\/10.1038\/sj.bjc.6602513.","journal-title":"Br J Cancer"},{"key":"2848_CR16","unstructured":"NCCN Guidelines Version 2.2025 Pancreatic Adenocarcinoma."},{"issue":"1","key":"2848_CR17","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1186\/s12885-019-5790-2","volume":"19","author":"AG Morganti","year":"2019","unstructured":"Morganti AG, Cellini F, Buwenge M, et al. Adjuvant chemoradiation in pancreatic cancer: impact of radiotherapy dose on survival. BMC Cancer. 2019;19(1):569. https:\/\/doi.org\/10.1186\/s12885-019-5790-2.","journal-title":"BMC Cancer"},{"issue":"12","key":"2848_CR18","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1002\/cncr.28047","volume":"119","author":"WA Hall","year":"2013","unstructured":"Hall WA, Colbert LE, Liu Y, et al. The influence of adjuvant radiotherapy dose on overall survival in patients with resected pancreatic adenocarcinoma. Cancer. 2013;119(12):2350\u20137. https:\/\/doi.org\/10.1002\/cncr.28047.","journal-title":"Cancer"},{"key":"2848_CR19","doi-asserted-by":"publisher","unstructured":"Karyn A, Goodman WF, Regine LA, Dawson et al. Radiation Therapy Oncology Group Consensus Panel Guidelines for the Delineation of the Clinical Target Volume in the Postoperative Treatment of Pancreatic Head Cancer. Int J Radiat Oncol Biol Phys 2012 July 01; 83(3): 901\u20138. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.01.022","DOI":"10.1016\/j.ijrobp.2012.01.022"},{"key":"2848_CR20","doi-asserted-by":"crossref","unstructured":"Lawrence B, Marks ED, Yorke A, Jackson et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S10-9. doi:0.1016\/j.ijrobp.2009.07.1754.","DOI":"10.1016\/j.ijrobp.2009.07.1754"},{"issue":"3 Suppl","key":"2848_CR21","doi-asserted-by":"publisher","first-page":"S101","DOI":"10.1016\/j.ijrobp.2009.05.071","volume":"76","author":"D Brian","year":"2010","unstructured":"Brian D, Kavanagh CC, Pan, et al. Radiation dose-volume effects in the stomach and small bowel. QUANTEC: organ specific paper. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S101\u20137. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.05.071.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"2848_CR22","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1097\/COC.0b013e31821f876a","volume":"35","author":"M Brandon","year":"2012","unstructured":"Brandon M, Barney KR, Oliver, et al. Clinical Outcomes and dosimetric considerations using stereotactic body radiotherapy and abdominopelvic tumors. Am J Clin Oncol. 2012;35(6):537\u201342. https:\/\/doi.org\/10.1097\/COC.0b013e31821f876a.","journal-title":"Am J Clin Oncol"},{"key":"2848_CR23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/1748-717X-8-148","volume":"8","author":"T Angelo Tozzi","year":"2013","unstructured":"Angelo Tozzi T, Comito F, Alongi, et al. SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience. Radiat Oncol. 2013;8:148. https:\/\/doi.org\/10.1186\/1748-717X-8-148.","journal-title":"Radiat Oncol"},{"issue":"3","key":"2848_CR24","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1177\/1533034616650778","volume":"16","author":"L Tiziana Comito","year":"2017","unstructured":"Tiziana Comito L, Cozzi E, Clerici, et al. Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study. Technol Cancer Res Treat. 2017;16(3):295\u2013301. https:\/\/doi.org\/10.1177\/1533034616650778.","journal-title":"Technol Cancer Res Treat"},{"key":"2848_CR25","doi-asserted-by":"publisher","unstructured":"Chang DK, Johns AL, Merrett ND et al. Margin Clearance and Outcome in Resected Pancreatic Cancer. J Clin Oncol 27, 2855\u20132862(2009), Volume 27, Number 17. https:\/\/doi.org\/10.1200\/JCO.2008.20.5104","DOI":"10.1200\/JCO.2008.20.5104"},{"issue":"3","key":"2848_CR26","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/SLA.0000000000001731","volume":"265","author":"O Strobel","year":"2017","unstructured":"Strobel O, Hank T, Hinz U, Bergmann F, et al. Pancreatic Cancer Surgery: The New R-status Counts. Ann Surg. 2017;265(3):565\u201373. https:\/\/doi.org\/10.1097\/SLA.0000000000001731.","journal-title":"Ann Surg"},{"key":"2848_CR27","volume-title":"Version 5; US Department of Health and Human Services","author":"Common Terminology Criteria for Adverse Events (CTCAE)","year":"2017","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). Version 5; US Department of Health and Human Services. Frederick, MD, USA: National Institutes of Health, National Cancer Institute; 2017."},{"issue":"8","key":"2848_CR28","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1001\/archsurg.1985.01390320023008","volume":"120","author":"MH Kalser","year":"1985","unstructured":"Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant Combined Radiation and Chemotherapy Following Curative Resection. Arch Surg. 1985;120(8):899\u2013903. https:\/\/doi.org\/10.1001\/archsurg.1985.01390320023008.","journal-title":"Arch Surg"},{"issue":"1","key":"2848_CR29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s12029-010-9203-7","volume":"43","author":"JC Rwigema","year":"2012","unstructured":"Rwigema JC, Heron DE, Parikh SD, et al. Adjuvant stereotactic body radiotherapy for resected pancreatic adenocarcinoma with close or positive margins. J Gastrointest Cancer. 2012;43(1):70\u20136. https:\/\/doi.org\/10.1007\/s12029-010-9203-7.","journal-title":"J Gastrointest Cancer"},{"key":"2848_CR30","doi-asserted-by":"publisher","unstructured":"Bernard ME, Sutera PA, Iarrobino NA, et al. Initial Results of a Prospective Study of Adjuvant Pancreatic Stereotactic Body Radiation Therapy for Close or Positive Margins. Adv Radiation Oncol. 2019;4294\u2013301. https:\/\/doi.org\/10.1016\/j.adro.2018.11.007.","DOI":"10.1016\/j.adro.2018.11.007"},{"key":"2848_CR31","doi-asserted-by":"crossref","unstructured":"Ross A, Abrams KA, Winter, Karyn A, Goodman et al. NRG Oncology\/RTOG 0848: Results after adjuvant chemotherapy +\/- chemoradiation for patients with resected periampullary pancreatic adenocarcinoma (PA). Oral Abstract Session 4005, ASCO. 2024.","DOI":"10.1200\/JCO.2024.42.16_suppl.4005"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-026-02848-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-026-02848-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-026-02848-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T03:03:26Z","timestamp":1781147006000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13014-026-02848-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2848"],"URL":"https:\/\/doi.org\/10.1186\/s13014-026-02848-3","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the institutional research ethics committee (Comitato Etico Indipendente IRCCS Humanitas Research Hospital) on May 18th 2021 and registered on ClinicalTrials.gov (NCT05043857). The investigation was performed in accordance with the Helsinki Declaration and informed consent was obtained from all patients before enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"L.R. reports consulting fees from AstraZeneca, Basilea, Bayer, BMS, Eisai, Exelixis, Genenta, Hengrui, Incyte, Ipsen, IQVIA, Lilly, MSD, Nerviano Medical Sciences, Roche, Servier, Taiho Oncology, Zymeworks; lecture fees from AstraZeneca, Bayer, Eisai, Gilead, Incyte, Ipsen, Merck Serono, Roche, Sanofi, Servier; travel expenses from AstraZeneca; research grants (to Institution) from Agios, AstraZeneca, BeiGene, Eisai, Exelixis, Fibrogen, Incyte, Ipsen, Lilly, MSD, Nerviano Medical Sciences, Roche, Zymeworks.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}